Published in Medical Letter on the CDC and FDA, September 23rd, 2007
This funding increases the total value of GenVec's three-year agreement from $15.2 million to $17.5 million. The additional funds will be used primarily for expanded development activities. Under the terms of the agreement, GenVec is responsible for the development, production and regulatory approval of the vaccine, while DHS is responsible for conducting...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.